Trial Profile
A Model for the Implementation of the Cervical Cancer Screening and HPV Vaccination in the Emergency Department: a Pilot Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- 21 Aug 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 05 Jun 2010 New trial record